Clinical Trials Logo

AMD clinical trials

View clinical trials related to AMD.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03845582 Active, not recruiting - Clinical trials for Age Related Macular Degeneration

Phase 3 Study of ALK-001 in Geographic Atrophy

SAGA
Start date: May 7, 2019
Phase: Phase 3
Study type: Interventional

This is a double-masked, multicenter, randomized, placebo-controlled clinical trial, evaluating the efficacy and safety of ALK-001 in participants with Geographic Atrophy (GA) secondary to age-related macular degeneration (AMD). Up to 200 participants will receive ALK-001 while up to 100 participants will receive a placebo.

NCT ID: NCT03803631 Active, not recruiting - AMD Clinical Trials

CNV in AMD Analyzed by OCT Angiography Under IntravitreaL Eylea (COCTAEyl)

COCTAEyl
Start date: April 4, 2018
Phase:
Study type: Observational

The main objective of this study is to analyze a new noninvasive imaging examination, OCT angiography, in the evaluation of neovascular remodeling and early signs of recurrence of wet AMD undergoing treatment on OCTA and to correlate OCTA findings with SD-OCT findings.

NCT ID: NCT03478865 Active, not recruiting - AMD Clinical Trials

Vitamin A Palmitate Supplementation in People With Age-Related Macular Degeneration (and Without Reticular Pseudodrusen) and Delayed Dark Adaptation

Start date: April 20, 2018
Phase: Early Phase 1
Study type: Interventional

Background: Age-related macular degeneration (AMD) is an eye disease. It is the leading cause of vision loss in people over 55 in the U.S. Changes in the eye can make it difficult for the eye to adjust to low light. This is known as dark adaptation. Identifying and watching the early to middle stages of AMD and changes in dark adaptation might help researchers develop new treatments to stop the disease before it becomes severe. Taking vitamin A might help improve vision in people with AMD. Objectives: To see if taking 16,000 IU of vitamin A per day improves vision in people with AMD. Also to improve understanding of AMD and associated dark adaptation. Eligibility: Adults ages 50 and older with AMD and normal liver function Design: Participants will be screened with: Medical and eye disease history Eye exam: The pupil will be dilated with eye drops. Pictures will be taken of the retina and the inside of the eye. Including the screening visit, participants will have at least 5 visits. They will be about once a month over 6 months. Visits include: Questions about eye problems in certain light Eye exam Blood and urine tests Dark adaptation protocol: Participants will sit at a machine in a dark room. They will look into the machine and push a button when they see a light. This lasts 20-30 minutes. Participants will take a vitamin A supplement by mouth once a day for 2 months. They will record when they take the pills in a diary.

NCT ID: NCT02868424 Active, not recruiting - Clinical trials for Macular Degeneration

Treatment of Age-related Macular Degeneration by Fetal Retinal Pigment Epithelial Cells Transplantation

Start date: February 13, 2016
Phase: Early Phase 1
Study type: Interventional

Early Phase I Study of the Safety and Preliminary Efficacy of Human Fetal Retinal Pigment Epithelial(fRPE) Cells Subretinal Transplantation in Age-Related Macular Degeneration(AMD) Patients

NCT ID: NCT01766596 Active, not recruiting - Glaucoma Clinical Trials

Study the Signs of Ocular Degeneration in a Population Cohort (Dijon 3C Montrachet Cohort)

3C
Start date: October 2009
Phase: N/A
Study type: Interventional

The aim of the study proposed in Dijon is above all to focus on the possible relationship between age-related ocular pathologies (AMD and glaucoma) and et les degenerative neurological and cardiac pathologies. The principal objective is to seek in subjects who have undergone cerebral MRI and echocardiography, associations between the thickness of postganglionic fibers measured by Optical Coherence Tomography at the 7th year (n=1500) and signs of cerebral impairment (psycho-cognitive tests, circulation time, MRI signs). This association will be studied after taking into account the principal environmental (particularly dietary) and genetic risk factors.